Second Quarter 2010

2010-07-20

DISCLAIMER

In order to utilize the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.

Q2 2010 – Strong sales growth in the US

- Revenues amounted to SEK 510 M
  - Revenues, excluding Tracleer, increased by 9% in CER and by 3% in SEK
  - Sales in North America increased by 38% in CER, and by 32% in SEK
  - Sales in Europe, excluding Tracleer, increased by 3% in CER, corresponding to -6% in SEK
  - Sales of Kineret® increased by 10% in CER, and by 2% in SEK
  - Sales of Orfadin® increased by 15% in CER, and by 5% in SEK
  - Total ReFacto® increased by 7% in CER, and by 6% in SEK
- EBITA was SEK 59.6 M
- Core EPS was 0.21 SEK
- Liquid funds and short-term investments were 219.9 on June 30
  - Bank loans amounted to SEK 1,347.8 M on June 30

Q2 2010, and after the period - Important R&D progress and business deals

- Exclusive rights to Ruconest® for Hereditary Angioedema (HAE) received for 24 EU countries as well as in Norway, Iceland and Switzerland
- Decision to advance Kiobrina® into a phase III development

Events after the period

- Ruconest® CHMP positive opinion received June 24
  - EC centralized procedure approval expected Q32010
- Intention to form a commercial alliance with Chinese company Dongbao announced July 6
- The European Medicines Agency issued positive rFVIIIFc orphan drug opinion June 2
- Decision to proceed rFVIIIFc into registrational studies announced July 9
  - Prolonged half-life compared to Advate, across all patients and dose levels
- rFIXFc phase I/II study results demonstrating approximately three-fold half-life increase presented July 11 at the WFH Congress

Q2 2010 – Revenues up 9% and EBITA up 13%, despite EU price pressure

Amounts in SEK million	Apr 1 - Jun 30 2010	2009	Pro forma 2009	Jan 1 - Jun 30 2010	2009	Pro forma 2009	Full year 2009
Total revenues, Constant Exchange Rate	535,9	319,9	510,9	1 060,2	675,1	1 054,1	1 297,0
Total revenues, reported	509,6	319,9	510,9	997,7	675,1	1 054,1	1 297,0
Gross profit	309,5	240,6	356,1	622,6	483,1	720,8	921,3
Operating profit/loss before amortizations, restructuring and other one-time expenses (EBITA)	59,6	-1,0	52,6	113,8	22,4	142,1	68,0
Profit/loss for the period before restructuring and other one-time expenses	-7,0	16,8		-12,4	-6,9		32,5
Profit/loss for the period	-11,6	16,8		-64,0	-6,9		32,5
Earnings/loss per share after tax [1)] (SEK)	-0,03	0,17		-0,17	-0,07		0,32
Core EPS [1)] (SEK)	0,21	0,29		0,48	0,17		0,84
Restructuring and other one-time expenses	4,6	–		51,6	–		–
Research and development expenses	113,4	162,2		241,1	306,0		569,4
Liquid funds and short-term investments	219,9	341,2		219,9	341,2		306,6

[1)] Comparison numbers adjusted for new share issue completed in January 2010.

Q2 2010 - Sales Kineret up 10% and Orfadin up 15%

Amounts in SEK million	Apr 1 - Jun 30 reported 2010	Apr 1 - Jun 30 CER 2010	Apr 1 - Jun 30 2009	Jan 1 - Jun 30 reported 2010	Jan 1 - Jun 30 CER 2010	Jan 1 - Jun 30 2009
ReFacto®	177,6	179,6	167,4	304,8	311,0	370,5
of which Manufacturing revenues	*117,8*	*117,8*	*95,1*	*190,9*	*190,9*	*231,7*
of which Co-promotion	*22,6*	*23,9*	*28,9*	*47,2*	*49,6*	*47,1*
of which Royalty	*37,2*	*37,9*	*43,4*	*66,7*	*70,5*	*91,7*
Kineret®	113,0	121,0	110,4	217,6	237,5	214,4
Orfadin®	79,3	86,8	75,7	162,4	179,2	152,0
Kepivance®	28,0	29,7	26,9	57,0	62,8	56,5
Ammonaps®	17,5	19,4	18,0	36,4	40,0	36,3
Yondelis®	8,8	9,5	11,5	17,8	19,0	18,7
Willfact®	2,7	2,8	–	4,5	4,6	–
Other product revenues	82,7	87,1	79,3	167,5	176,4	158,9
Other revenues	–	–	3,9	23,8	23,8	9,5
Total revenues continued products	**509,6**	**535,9**	**493,1**	**991,8**	**1 054,3**	**1 016,8**
Tracleer	–	–	17,8	5,9	5,9	37,3
Total revenues	**509,6**	**535,9**	**510,9**	**997,7**	**1 060,2**	**1 054,1**

Q2 2010 - US sales up 38% (25 % in H2 2010)

	Apr 1 - Jun 30			Jan 1 - Jun 30		
	reported	CER		reported	CER	
Amounts in SEK million	**2010**	**2010**	**2009**	**2010**	**2010**	**2009**
Nordic	80,5	83,7	95,9	167,3	173,7	189,2
Europe	135,6	151,3	150,2	285,2	315,1	291,7
North America	98,9	103,7	74,8	173,7	191,0	152,3
RoW	5,4	5,0	8,9	22,4	23,1	22,6
Total product revenues	**320,4**	**343,7**	**329,8**	**648,6**	**702,9**	**655,8**
Manufacturing revenues	117,8	117,8	95,1	190,9	190,9	231,7
Co-promotion	34,2	36,5	38,7	67,7	72,1	65,4
Royalty	37,2	37,9	43,4	66,7	70,5	91,7
Other revenues	–	–	3,9	23,8	23,8	9,5
Total revenues	**509,6**	**535,9**	**510,9**	**997,7**	**1 060,2**	**1 054,1**

Strong and low risk emerging development pipeline

Indication	Product/Project	Partner	Phase I	Phase II	Phase III	Reg phase
Hemophilia B	rFIXFc	BiogenIdec				
Hemophilia A	rFVIIIFc	BiogenIdec				
Fat malabsorption in premature infants	Kiobrina®					
Fat malabsorption	Exinalda®					
Rh-Immunization	Sym001	Symphogen				
Autoimmune platelet disorder (ITP)	Sym001	Symphogen				

Development news flow

Activity	Expected completion
rFVIIIFc (hemophilia A): phase III, first patient in (FPI)	H2 2010
Sym001 (ITP): phase II study	H2 2010
Kiobrina® (fat malarbsorption): phase III, (FPI)	H1 2011
rFIXFc (hemophilia B): phase III	2011/2012

Outlook 2010 and long term objectives unchanged

- The company continues to closely monitor the uncertainty in the European pharmaceutical market
- Operating income (EBITA) expected to increase 30-35% in CER
- Revenue growth of 8-10% in CER
- Gross profit margin expected to be between 63-65%
- Operating expenses expected to decrease by 10-12%

- Long term business target is to by 2015:
  - Grow revenues to 5 BSEK
  - Reach an EBITA margin of >30 %.

Q2 2010 Summary – Platform for near and long term profitable growth strengthened

- Revenues increased by 9% in CER driven by growth products
- EBITA grew by 13% in CER
- Important addition to the product portfolio further strengthens the growth platform
- Successful business deal with Chinese partner may further strengthen the growth platform
- Kiobrina® advancing into phase III development
- Decision to move rFVIIIFc into registrational phase July 9

- Near and long term growth guidance maintained

www.sobi.com

2010-07-20